Using Therapeutic Drug Monitoring to Treat KPC-Producing Central Nervous System Infection With Ceftazidime/Avibactam

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2020 Sep 23

PMID 32964066

Citations 18

Authors

Mohamad Yasmin

Jennifer Hanrahan

Steven Marshall

Thomas P Lodise

Liang Chen

Federico Perez

Barry Kreiswirth

Robert A Bonomo

Affiliations

Soon will be listed here.

Abstract

This report describes the treatment of carbapenemase (KPC)-3-producing multidrug-resistant with ceftazidime/avibactam (CAZ-AVI) in a patient who developed postneurosurgical meningitis and bacteremia. Therapeutic drug monitoring of cerebrospinal fluid and blood samples demonstrated CAZ-AVI concentration levels 20-fold greater than the minimum inhibitory concentration in the first 60 minutes postinfusion, providing evidence for the utility of CAZ-AVI in treating KPC- central nervous system infections.

Citing Articles

Treatment of pediatric central nervous system infection caused by carbapenem-resistant with ceftazidime/avibactam, two cases report and literature review.

Qing L, Zhang H, Pan X, Liu Z Front Pharmacol. 2025; 16:1532608.

PMID: 40061952 PMC: 11885231. DOI: 10.3389/fphar.2025.1532608.

Experience in Ceftazidime-Avibactam for treatment of MDR BGN infection in Oncologic Children.

Hoshino W, da Silva A, Pignatari A, Gales A, Carlesse F Braz J Infect Dis. 2025; 29(2):104515.

PMID: 39985933 PMC: 11893299. DOI: 10.1016/j.bjid.2025.104515.

Meropenem-vaborbactam as intrathecal-sparing therapy for the treatment of carbapenem-resistant K. pneumoniae shunt-related ventriculitis: two case reports and review of the literature.

Giuliano G, Sambo M, Castellani P, Benedetti S, Tarantino F, Tumbarello M Eur J Clin Microbiol Infect Dis. 2024; 44(1):193-196.

PMID: 39531123 DOI: 10.1007/s10096-024-04986-6.

Ceftazidime-Avibactam for the Treatment of Central Nervous System Infection Caused by Pan Drug-Resistant Carbapenem-Resistant Klebsiella Pneumoniae: A Case Report.

Zhang Y, Hou G, Zhang L, Li S Infect Drug Resist. 2024; 17:3501-3506.

PMID: 39157745 PMC: 11328857. DOI: 10.2147/IDR.S465004.

A Difficult Case of Ventriculitis in a 40-Year-Old Woman with Acute Myeloid Leukemia.

Rubino R, Trizzino M, Pipito L, Sucato G, Santoro M, Maugeri R Antibiotics (Basel). 2024; 13(5).

PMID: 38786160 PMC: 11117259. DOI: 10.3390/antibiotics13050432.

References

van Duin D, Bonomo R . Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016; 63(2):234-41. PMC: 4928383. DOI: 10.1093/cid/ciw243. View

Endimiani A, Hujer K, Hujer A, Pulse M, Weiss W, Bonomo R . Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2010; 55(1):82-5. PMC: 3019638. DOI: 10.1128/AAC.01198-10. View

Singh R, Kim A, Tanudra M, Harris J, McLaughlin R, Patey S . Pharmacokinetics/pharmacodynamics of a β-lactam and β-lactamase inhibitor combination: a novel approach for aztreonam/avibactam. J Antimicrob Chemother. 2015; 70(9):2618-26. DOI: 10.1093/jac/dkv132. View

Crass R, Pai M . Pharmacokinetics and Pharmacodynamics of β-Lactamase Inhibitors. Pharmacotherapy. 2018; 39(2):182-195. DOI: 10.1002/phar.2210. View

Berkhout J, Melchers M, van Mil A, Seyedmousavi S, Lagarde C, Schuck V . Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection. Antimicrob Agents Chemother. 2015; 60(1):368-75. PMC: 4704241. DOI: 10.1128/AAC.01269-15. View

Vishwanathan K, Mair S, Gupta A, Atherton J, Clarkson-Jones J, Edeki T . Assessment of the mass balance recovery and metabolite profile of avibactam in humans and in vitro drug-drug interaction potential. Drug Metab Dispos. 2014; 42(5):932-42. DOI: 10.1124/dmd.113.055335. View

van Duin D, Lok J, Earley M, Cober E, Richter S, Perez F . Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2017; 66(2):163-171. PMC: 5850032. DOI: 10.1093/cid/cix783. View

Holyk A, Belden V, Lee J, Musick W, Keul R, Britz G . Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. J Antimicrob Chemother. 2017; 73(1):254-256. DOI: 10.1093/jac/dkx358. View

Lutsar I, McCracken Jr G, Friedland I . Antibiotic pharmacodynamics in cerebrospinal fluid. Clin Infect Dis. 1998; 27(5):1117-27, quiz 1128-9. DOI: 10.1086/515003. View

10.

Falcone M, Paterson D . Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. J Antimicrob Chemother. 2016; 71(10):2713-22. DOI: 10.1093/jac/dkw239. View

11.

Veillette J, Truong J, Forland S . Pharmacokinetics of Ceftazidime-Avibactam in Two Patients With KPC-Producing Klebsiella pneumoniae Bacteremia and Renal Impairment. Pharmacotherapy. 2016; 36(11):e172-e177. DOI: 10.1002/phar.1840. View

12.

Won S, Munoz-Price L, Lolans K, Hota B, Weinstein R, Hayden M . Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis. 2011; 53(6):532-40. DOI: 10.1093/cid/cir482. View

13.

Nau R, Sorgel F, Prange H . Pharmacokinetic optimisation of the treatment of bacterial central nervous system infections. Clin Pharmacokinet. 1998; 35(3):223-46. DOI: 10.2165/00003088-199835030-00005. View

14.

Coleman K, Levasseur P, Girard A, Borgonovi M, Miossec C, Merdjan H . Activities of ceftazidime and avibactam against β-lactamase-producing Enterobacteriaceae in a hollow-fiber pharmacodynamic model. Antimicrob Agents Chemother. 2014; 58(6):3366-72. PMC: 4068505. DOI: 10.1128/AAC.00080-14. View